MX394435B - Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina. - Google Patents

Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina.

Info

Publication number
MX394435B
MX394435B MX2019013397A MX2019013397A MX394435B MX 394435 B MX394435 B MX 394435B MX 2019013397 A MX2019013397 A MX 2019013397A MX 2019013397 A MX2019013397 A MX 2019013397A MX 394435 B MX394435 B MX 394435B
Authority
MX
Mexico
Prior art keywords
therapeutic agent
lewy body
body disease
disease containing
pyrazoloquinoline derivative
Prior art date
Application number
MX2019013397A
Other languages
English (en)
Spanish (es)
Other versions
MX2019013397A (es
Inventor
Mai MIYAMOTO
Yukio Ishikawa
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2019013397A publication Critical patent/MX2019013397A/es
Publication of MX394435B publication Critical patent/MX394435B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2019013397A 2017-06-01 2018-05-30 Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina. MX394435B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513727P 2017-06-01 2017-06-01
PCT/JP2018/020650 WO2018221551A1 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体を含有するレビー小体病治療剤

Publications (2)

Publication Number Publication Date
MX2019013397A MX2019013397A (es) 2020-02-07
MX394435B true MX394435B (es) 2025-03-12

Family

ID=64456542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013397A MX394435B (es) 2017-06-01 2018-05-30 Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina.

Country Status (13)

Country Link
US (1) US11311530B2 (https=)
EP (1) EP3632438B1 (https=)
JP (1) JP7269875B2 (https=)
KR (1) KR20200010220A (https=)
CN (1) CN110612102A (https=)
AU (1) AU2018278422B2 (https=)
BR (1) BR112019023552A2 (https=)
CA (1) CA3061884A1 (https=)
ES (1) ES2961554T3 (https=)
IL (1) IL270357B2 (https=)
MX (1) MX394435B (https=)
TW (1) TWI784006B (https=)
WO (1) WO2018221551A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5318759A (en) 1976-08-02 1978-02-21 Nisshin Oil Mills Ltd Method of making fried beancurd
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
DK0760819T3 (da) 1994-05-24 2000-10-09 Hoffmann La Roche Tricykliske dicarbonylderivater
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
BR0313262A (pt) 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
WO2005118583A1 (en) 2004-05-28 2005-12-15 Millennium Pharmaceuticals, Inc. 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
CA2622605A1 (en) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. Heterocycle compound, and production process and application thereof
CA2671980C (en) 2006-12-13 2015-05-05 Aska Pharmaceutical Co., Ltd. Quinoxaline derivatives
WO2008072778A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. 尿路系疾患の処置剤
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びcns障害の治療のためのそれらの使用
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
WO2010101230A1 (ja) 2009-03-05 2010-09-10 アステラス製薬株式会社 キノキサリン化合物
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
AP2012006631A0 (en) 2010-08-12 2012-12-31 Boehringer Ingelheim Int 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
RS54834B1 (sr) 2010-09-07 2016-10-31 Astellas Pharma Inc Jedinjenja pirazolokvinolina
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
PT2573073E (pt) 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
WO2013051639A1 (ja) 2011-10-07 2013-04-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体
TW201439091A (zh) 2013-04-05 2014-10-16 Eisai R&D Man Co Ltd 吡啶基吡唑并喹啉化合物
EP2982675B1 (en) * 2013-04-05 2017-08-16 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤

Also Published As

Publication number Publication date
ES2961554T3 (es) 2024-03-12
IL270357A (https=) 2020-02-27
BR112019023552A2 (pt) 2020-06-02
US11311530B2 (en) 2022-04-26
IL270357B2 (en) 2024-02-01
TW201902479A (zh) 2019-01-16
EP3632438B1 (en) 2023-08-23
JP7269875B2 (ja) 2023-05-09
AU2018278422B2 (en) 2022-03-17
RU2019135690A (ru) 2021-07-13
EP3632438A4 (en) 2020-12-23
MX2019013397A (es) 2020-02-07
AU2018278422A1 (en) 2019-11-21
WO2018221551A1 (ja) 2018-12-06
IL270357B1 (en) 2023-10-01
TWI784006B (zh) 2022-11-21
JPWO2018221551A1 (ja) 2020-04-02
CN110612102A (zh) 2019-12-24
KR20200010220A (ko) 2020-01-30
CA3061884A1 (en) 2019-10-29
RU2019135690A3 (https=) 2021-08-25
US20200155541A1 (en) 2020-05-21
EP3632438A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
MX392609B (es) Agente terapéutico para la demencia que combina derivado de pirazoloquinolina y memantina.
MX2019013397A (es) Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina.
SG11201809859VA (en) Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
PH12017502171B1 (en) PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
BR112018011475A2 (pt) compostos e métodos para modulação de quinase e indicação para a mesma
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
GEP20257716B (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
MX2019013198A (es) Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9).
SG11201909595VA (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
MY199208A (en) Benzemesulfonamide compounds and their use as therapeutic agents
MX2019006697A (es) Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
CO2018002204A2 (es) Agentes antibacteriales que comprenden un pirazino [2,3-b]- [1,4] oxazin-3-ona o un sistema de anillo relacionado
BR112012004851B8 (pt) uso de um derivado de tiazol
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
SA519401827B1 (ar) [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه
PL3894411T3 (pl) Pochodne 7-fenoksy-N-(3-azabicyklo[3.2.1]oktan-8-ylo)-6,7-dihydro-5H-pirolo[1,2-b][1,2,4]triazolo-2-aminy i związki pokrewne jako modulatory gamma-sekretazy do leczenia choroby Alzheimera
MX2021007247A (es) Derivados de rapamicina.
MX384072B (es) Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa.
MX394882B (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
MY205197A (en) Methyllactam ring compound and pharmaceutical use thereof
MX2019002065A (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana.
CL2017003025A1 (es) Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios.